Pharmacyte Biotech Inc (OTCMKTS:PMCB) updated on the process of the compliance process completion of the Austrianova’s current Good Manufacturing Practices-compliant facility in Thailand. The encapsulation process of genetically modified human cells in the unique Cell-in-a-Box® capsules will be carried out in this facility. This are the same capsules that the company intends to use in its clinical trials targeting diseases like cancer and diabetes.
In the last trading session, the stock price of Pharmacyte declined over 5% to close the trading session at $.0910. The decline came at a share volume of 2.27 million compared to average monthly share volume of 1.44 million.
Uluru Inc (OTCMKTS:ULUR) reported that during last quarter, the company released encouraging interim data for its pharmaco-economic assessment being conducted in Europe. The biggest news came from Russia as it received marketing approval for the sale of Altrazeal® by the governing bodies. Also, the company started with the initial shipment of Altrazeal for Egypt and Saudi Arabia.
ULURU comes in the list of specialty pharmaceutical firms focused on the development of oral care and wound management products. In last trading session, the stock price of Uluru declined over 5% to close the trading session at $0.320. The decline came at a share volume of 20,527 compared to average share volume of 15,665.
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) reported that launch of its new Alevicyn SG Antipruritic Spray Gel for pain and Itch relief in Atopic Dermatitis. The spray is formulated with the Microcyn Technology and is meant to relive the pain, itching and burning experienced with several types of dermatoses, such as atopic dermatitis and radiation dermatitis.
In last trading session, the stock price of Oculus declined more than 5% to close the trading session at $$1.15. The decline came at a share volume of 129,876 compared to average monthly share volume of 530,758.